Previous 10 | Next 10 |
The FDA has approved Zynlonta (loncastuximab tesirine-lpyl) from ADC Therapeutics (ADCT) for diffuse large B-cell lymphoma.The biologic was given Priority Review status and approved ahead of its PDUFA date of May 21, 2021.ADC also has an expanded access program for Zynlonta.ADC shares are ...
Shares of ADC Therapeutics SA (NYSE:ADCT) traded today at $21.33, breaking its 52-week low. This new low was reached on below average trading volume as 76,000 shares traded hands, while the average 30-day volume is approximately 396,000 shares. In the past 52 weeks, shares of ADC Therape...
The following slide deck was published by ADC Therapeutics SA in conjunction with this event. For further details see: ADC Therapeutics (ADCT) Investor Presentation - Slideshow
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...
Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA ((ADCT)), announces the appointment of Eric Koo as the company's chief executive officer.Koo has more than 25 years of pharmaceutical industry and business management exper...
Senior pharmaceutical executive with deep oncology experience in Asia formerly of Takeda, MSD, Bayer and Pfizer Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the appointment of Eric Koo,...
The following slide deck was published by ADC Therapeutics SA in conjunction with their 2020 Q4 earnings call. For further details see: ADC Therapeutics SA 2020 Q4 - Results - Earnings Call Presentation
Image source: The Motley Fool. ADC Therapeutics SA (NYSE: ADCT) Q4 2020 Earnings Call Mar 18, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: ADC Therapeutics SA (ADCT) Q4 2020 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q4 2020 Earnings Conference Call March 18, 2021 8:30 AM ET Company Participants Amanda Hamilton - Investor Relations Manager Chris Martin - Chief Executive Officer Jay Feingold - Chief Medical Officer Jenn Creel - Chief Financial Officer Jennifer Herron - Senior Vic...
ADC Therapeutics (ADCT): Q4 GAAP EPS of -$0.73.Cash and cash equivalents were $439.2 million as of December 31, 2020, compared to $115.6 million as of December 31, 2019.Press Release For further details see: ADC Therapeutics reports Q4 results
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...